Pharmacologic and antitumor effects of 1,2:5,6-dianhydrogalactitol (NSC-132313)
Németh, L.; Institóris, L.; Somfai, S.; Gál, F.; Pályi, I.; Sugár, J.; Csuka, O.; Szentirmay, Z.; Kellner, B.
Cancer ChemoTherapy Reports 56(5): 593-602
1972
ISSN/ISBN: 0069-0112 PMID: 4652589 Document Number: 49162
Document emailed within 1 workday
Related Documents
Sleptsova, S.I. 1987: Effects of various pharmacologic and non-pharmacologic agents on the mother and fetus (data for the health promotion propaganda) Akusherstvo i Ginekologiia 12: 68-71Dorr, R.T.; Alberts, D.S.; Einspahr, J.; Mason-Liddil, N.; Soble, M. 1987: Experimental dacarbazine antitumor activity and skin toxicity in relation to light exposure and pharmacologic antidotes Cancer Treatment Reports 71(3): 267-272
Bozeman, E.N.; Srivatsan, S.; Mohammadi, H.; Daniels, D.; Shashidharamurthy, R.; Selvaraj, P. 2012: Ukrain, a plant derived semi-synthetic compound, exerts antitumor effects against murine and human breast cancer and induce protective antitumor immunity in mice Experimental Oncology 34(4): 340-347
1973: Pharmacologic effects of anisodamine Zhonghua yi xue za zhi 53(5): 269-273
Martínková, J. 1991: Pharmacologic effects on portal circulation Casopis Lekaru Ceskych 130(12): 374-378
Ohnuma, T.; Roboz, J.; Waxman, S.; Mandel, E.; Martin, D.S.; Holland, J.F. 1980: Clinical pharmacologic effects of thymidine plus 5-FU Cancer Treatment Reports 64(12): 1169-1177
Seeman, M.V. 1981: Pharmacologic features and effects of neuroleptics Canadian Medical Association Journal 125(8): 821-826
Costa, F.V. 1988: Clinical pharmacologic aspects of mepartricin. Possible pharmacologic interference with digitaloids and anticoagulants Minerva Urologica e Nefrologica 40(2 Suppl): 5-6
Espana, P.; Wiernik, P.H.; Walker, M.D. 1978: Phase II study of dianhydrogalactitol in malignant glioma Cancer Treatment Reports 62(8): 1199-1200
Fan, Y.J.; Han, R.; Zhou, J.; Li, M. 1987: Experimental studies of the combination of vincristine and 1,2:5,6-dianhydrogalactitol Yao Xue Xue Bao 22(2): 98-102
Zuskin, E.; Mustajbegović, J.; Sitar-Srebocan, V. 1997: Pharmacologic study of the effects of the components of beer in vitro Lijecnicki Vjesnik 119(3-4): 103-105
Cheav, S.L.; Chalfoun-Mounayar, A.; Foussard-Blanpin, O. 1989: Pharmacologic effects of glycerolformal on the central nervous system Annales Pharmaceutiques Francaises 47(6): 353-360
Bifarini, G.; Trabalza, N.; Falconi, S.; Malà, L.; Favetta, P. 1990: Possible effects of pharmacologic prophylaxis for Mendelson's syndrome on newborns Minerva Anestesiologica 56(12): 1447-1450
Maynard, J.R.; Fintel, D.J.; Pitlick, F.A.; Nemerson, Y. 1976: Tissue factor in cultured cells: pharmacologic effects Laboratory Investigation; A Journal of Technical Methods and Pathology 35(6): 550-557
Vogel, C.L.; Winton, E.F.; Moore, M.R.; Sohner, S. 1976: Phase i trial of dianhydrogalactitol administered Iv in a weekly schedule Cancer Treatment Reports 60(7): 895-901
Munger, D.; Sternson, L.A.; Patton, T.F. 1978: Studies on the distribution of dianhydrogalactitol into the central nervous system of the rat Cancer Treatment Reports 62(3): 409-412
Blaschke, T.F.; Melmon, K.L. 1974: Clinical significance of pharmacologic effects of roentgen contrast media Der Internist 15(8): 439-443
Ghione, M. 1980: Side-effects of antitumor chemotherapy Minerva Medica 71(15): 1095-1099
Santarelli, L.; Gobbi, G.; Blier, P.; Hen, R.é 2002: Behavioral and physiologic effects of genetic or pharmacologic inactivation of the substance P receptor (NK1) Journal of Clinical Psychiatry 63(Suppl 11): 11-17
Gormus, B.J.; Basara, M.L.; Arneson, M.A.; Kaplan, M.E. 1980: Capping of mouse spleen lymphocyte C3 receptors: effects of pharmacologic agents Journal of Immunology 124(6): 2747-2753